gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · AVXLHealthcareBiotechnology

Anavex Life Sciences (AVXL)

$1.26+5.00%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$1.26▼ 83.13% in range
Nov 4, 2025Low $1.14 · High $7.47Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Anavex Life Sciences closed at $1.26 on Nov 4, up 5.00%, 83.7% below its 52-week closing high. Volume of 929.1K shares was 0.76× its 20-day average (below normal).

Split-adjusted performance: -21.2% over one month, -62.3% over six months, -83.7% over one year.

Short interest was 12.5M shares at the Oct 15 settlement, down 7.5% from the prior report (14.0% of float, 8.1 days to cover).

Market cap$116.8M92.7M shares
Revenue · quarter$0.00—
Diluted EPS$0.08—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range1.14 – 7.74−83.7% from high
Volume929.1K0.76× 20-day avg
Volatility · 60d74.4%Annualised
Short % of float14.0%8.1 days to cover
Net cash$118.3MCash $118.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −3.1%1M −21.3%3M −61.6%6M −62.3%YTD −64.6%1Y −83.7%3Y −77.1%5Y −92.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum16
Revenue growth—
Net margin—
Value (low P/E)—
Size38

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short12.5M−7.5% vs prior
Days to cover8.1Settled Oct 15
% of float14.0%
Short vol. 10d53.0%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
AVXLAnavex Life Sciences$1.26+5.00%−62.3%———$116.8M
ARMPArmata Pharmaceuticals$3.14+1.62%−65.3%+15.7%2953.8%—$116.8MCompare
ENGNenGene Therapeutics$1.72+6.17%−80.6%———$115.3MCompare
VYGRVoyager Therapeutics$1.87+2.19%−55.2%−39.1%−773.2%—$115.2MCompare
OTLKOutlook Therapeutics$0.4621+0.46%+99.4%−99.4%−233554.9%—$112.5MCompare
BDTXBlack Diamond Therapeutics$1.90+4.97%−32.6%———$109.2MCompare
HUMAHumacyte$0.4500+2.16%−54.2%+34.9%−9064.5%—$125.0MCompare
LENZLENZ Therapeutics$3.46−1.14%−64.3%+9.7%−581.8%—$108.7MCompare
NMRANeumora Therapeutics$0.5660−0.86%−75.7%———$106.3MCompare

News about Anavex Life Sciences

All news →
Anavex Life Sciences Corp. Investors Seeking Lead Plaintiff Role Have Until November 30th to Contact Bragar Eagel & Squire, P.C.GlobeNewswire Inc. · 1d ago▼ NegativeAnavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of DirectorsGlobeNewswire Inc. · 1d ago▲ PositiveLead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Tigo Energy, Inc. (TYGO), Fluence Energy, Inc. (FLNC), and Anavex Life Sciences Corp. (AVXL) Announced by Holzer & Holzer, LLCGlobeNewswire Inc. · 2d ago▼ NegativeANAVEX DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Anavex Life Sciences Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXLGlobeNewswire Inc. · 4d ago▼ NegativeKirby McInerney LLP Alerts Investors Who Acquired Anavex Life Sciences Corp. AVXL Securities Between November 26, 2025 and August 28, 2026 of Pending LawsuitGlobeNewswire Inc. · 6d ago▼ Negative

Quick answers

What does Anavex Life Sciences do?
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases.
What is AVXL's market cap?
$116.80M, based on the Nov 4 close of $1.26.
Does Anavex Life Sciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of AVXL is sold short?
12.5M shares, 14.0% of float, as of Oct 15, 2026.
What sector is AVXL in?
Healthcare, in the Biotechnology industry.

About Anavex Life Sciences

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

HQ: New York, NY34 employeesListed Aug 2, 2006anavex.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology